Difference between revisions of "MSK Biomarker Ctte"
Jump to navigation
Jump to search
| (35 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
| − | + | Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD | |
| − | + | <br />RSNA Staff Support: Susan Stanfa | |
| − | * [ | + | * [https://docs.google.com/spreadsheets/d/e/2PACX-1vTtFdmro0ILLuaCHj65SltPX7AIp2nDeAj4UXWrZGgDTs5WrstIgEr0UTRxY3mSZ6ZnRi6bRuWWHsMt/pubhtml?gid=1066960490&single=true Roster] |
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK. | The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK. | ||
| Line 9: | Line 9: | ||
'''Approved call summaries:''' | '''Approved call summaries:''' | ||
| − | *[[Media: | + | *[[Media:2021_09-28_QIBA_MSK_BC_Call_Summary-FINAL.pdf|September 28, 2021]] |
| − | *[[Media: | + | *[[Media:2021_08-24_QIBA_MSK_BC_Call_Summary-FINAL.pdf|August 24, 2021]] |
| − | *[[Media: | + | *[[Media:2021_07-27_QIBA_MSK_BC_Call_Summary-FINAL.pdf|July 27, 2021]] |
'''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | '''''[[MSK Biomarker Committee Call Summaries Archive]]''''' | ||
==Working Documents== | ==Working Documents== | ||
| + | *[[Media:2020_01-28_QIBA_Profile_MSK-cartilage.docx| QIBA MSK Profile 2020-01-28:]] ''MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease'' | ||
==Statistical Reference Documents== | ==Statistical Reference Documents== | ||
Revision as of 17:04, 23 November 2021
Co-chairs: Xiaojuan Li, PhD; Thomas M. Link, MD, PhD
RSNA Staff Support: Susan Stanfa
The MSK Biomarker Committee seeks to develop a quantitative Profile for MSK.
Meetings
Approved call summaries:
MSK Biomarker Committee Call Summaries Archive
Working Documents
- QIBA MSK Profile 2020-01-28: MR-based cartilage compositional biomarkers (T1ρ, T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease